Coronation Fund Managers’s Atara Biotherapeutics ATRA Stock Holding History

Coronation Fund Managers’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-7,927	Closed	-$3.26M	–	77
2019 Q4	$3.26M	Hold	7,927	–	–	0.11%	86
2019 Q3	$2.8M	Buy	7,927 +4,245	+115%	+$1.58M	0.1%	96
2019 Q2	$1.85M	Buy	3,682 +2,341	+175%	+$1.65M	0.07%	99
2019 Q1	$1.33M	Buy	+1,341	New	+$1.25M	0.05%	114

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Coronation Fund Managers's ATRA Position: Q1 2020 in Review

Coronation Fund Managers sold out of Atara Biotherapeutics (ATRA) in Q1 2020, closing a stake of 7,927 shares — an estimated $3.26M sold.

Coronation Fund Managers first reported a position in ATRA in Q1 2019 and held it in 4 quarters. The position peaked at $3.26M in Q4 2019. 111 funds tracked by Wall St. Rank hold ATRA as of Q1 2020.

Coronation Fund Managers reported no remaining Atara Biotherapeutics position as of Q1 2020 after selling out during the quarter.
Coronation Fund Managers sold 7,927 Atara Biotherapeutics shares in Q1 2020, an estimated $3.26M.
Coronation Fund Managers first reported a position in Atara Biotherapeutics in Q1 2019 and held it in 4 quarters.
Coronation Fund Managers's Atara Biotherapeutics position peaked at $3.26M in Q4 2019.
111 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2020.

Based on Coronation Fund Managers's 13F filing for Q1 2020, filed 12 May 2020.